Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy

AIDS

Volumn 13, Issue 2, 1999, Pages 203-212

  Pakker, Nadine G ^a   Kroon, Eugene D M B ^b   Roos, Marijke T L ^a   Otto, Sigrid A ^a   Hall, David ^c   Wit, Ferdinand W N M ^b   Hamann, Dörte ^a   Van der Ende, Marina E ^d   Claessen, Frans A P ^e   Kauffmann, Robert H ^f   Koopmans, Peter P ^g   Kroon, Frank P ^h   Ten Napel, Chris H H ⁱ   Sprenger, Herman G ^j   Weigel, Hugo M ^k   Montaner, Julio S G ^l   Lange, Joep M A ^b   Reiss, Peter ^b   Schellekens, Peter T A ^a,b   Miedema, Frank ^a,b,k  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f LEYENBURG HOSPITAL   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ MEDISCH SPECTRUM TWENTE   (Netherlands)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

Antiretroviral therapy; Long term immune reconstitution; Viral suppression

Indexed keywords

ANTIRETROVIRUS AGENT; CD27 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; MONOCLONAL ANTIBODY; NEVIRAPINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENCE; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; AGING; ANTI-HIV AGENTS; DIDANOSINE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; ZIDOVUDINE;

EID: 0033010260     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199902040-00008     Document Type: Article

References (37)

1. Graham NMH, Hoover DR, Park LP, et al.: Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med 1906, 124:1031-1038.
2. Carr A, Vella S, De Jong MD, et al.: A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS 1996, 10:635-641.
3. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
4. Schooley RT, Ramirez-Ronda C, Lange JMA, et al.: Virologic and immunologic benefits of initial therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 1996, 173:1354-1366.
5. Delta Coordinating Committee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
6. Autran B, Carcelain C, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
7. Pakker NG, Roos MTL, Van Leeuwen R, et al.: Patterns of T cell repopulation, viral load reduction and restoration of T cell function in human immunodefiency virus infected persons during therapy with different antiretrovirals. J AIDS Hum Retrovirol 1997, 16:318-326.
8. Koot M, Schellekens PTA, Mulder JW, et al.: Viral phenotype and T-cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine. J Infect Dis 1993, 168:733-736.
9. Bindels PJE, Krol A, Roos MTL, et al.: The predictive value of T cell function in vitro and pre AIDS zidovudine use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam. J Infect Dis 1995, 172:97-104.
10. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B: Lung-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998, 351:1682-1686.
11. Pakker NG, Notermans DW, De Boer RJ, et al.: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nature Med 1998, 4:208-214.
12. Monlaner JSG, Reiss P, Cooper DA, et al.: A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial. JAMA 1998, 279:930-937.
13. D'Aquila RT, Hughes MD, Johnson VA, et al.: Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV infection. Ann Intern Med 1996, 124:1019-1030.
14. De Jong MD, Vella S, Carr A, et al.: High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons docs not result in sustained suppression of viral replication. J Infect Dis 1997, 175:966-970.
15. 3: AIDS Clinical Trails Group protocol 208. J Infect Dis 1998, 172:1379-1383.
16. Richman DD, Havlir D, Corbeil J, et al.: Nevirapine resistance mutations of human immunodeficiency virus type-1 selected during therapy. J Virol 1994, 68:1660-1666.
17. Hamann D, Baars PA, Rep MHG, et al.: Phenotypic and functional separation of memory and effector human CD8pos T cells. J Exp Med 1997, 186:1407-1418.
18. Roederer M, Gregson Dubs J, Anderson MT, Raju PA, Herzenberg LA, Herzenberg L: CD8 naïve T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995, 95:2061-2066.
19. Bloemena T, Roos MTL, van Heijst JIAM, Vossen JMJJ, Schellekens PTA: Whole-blood lymphocyte cultures. J. Immunol Meth 1989, 122:161-167.
20. Roos MTL, Prins M, Koot M, et al.: Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS. AIDS 1998, 12:1745-1751.
21. Mulder, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S: A rapid and simple PCR assay for quantification of human immunodeficiency virus type-1 RNA in plasma; application to acute retroviral infection. J Clin Microbiol 1994, 32:292-300.
22. Mulder J, Resnick R, Saget B, et al.: A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J Clin Microbiol 1997, 35:1278-1280.
23. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 307-310.
24. Mackall CL, Fleisher TA, Brown M, et al.: Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995, 332:143-149.
25. Hakim FT, Cepeda R, Kaimei S, et al.: Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997, 90:3789-3798.
26. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
27. Roberts NA, Craig JC, Sheldon J: Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: therapy and practice. AIDS 1998, 12:453-460.
28. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
29. Carr A, Samaras K, Chrisholm DJ, Cooper D: Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insuline resistance. Lancet 1998, 351:1881-1883.
30. Weverling GJ, Lange JMA, Jurriaans S, et al.: Alternative multidrug regimen provides improved suppression of HIV-1 reputation over triple therapy. AIDS 1998, 12:F117-F122.
31. Reijers MHE, Weverling GJ, Jurriaans S, et al.: Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998, 352:185-190.
32. Kelleher AD, Carr A, Zaunders J, Cooper DA: Alterations in the immune response of human immunodeficiency virus (HIV) infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173:321-329.
33. McCune JM, Loftus R, Schmidt DK, et al.: High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest 1998, 101:2301-2308.
34. Cohen J: Failure isn't what it used to be ... but neither is success. Science 1998, 279:1133-1134.
35. Kaufmann D, Pantaleo G, Sudre P, Telenti A: CD4-count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998, 351:723-724.
36. Levitz SM: Improvement in CD4+ cell counts despite persistently detectable HIV load. New Engl J Med 1998, 338:1074-1075.
37. Gorochov G, Neumann AU, Kereveur A, et al.: Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nature Med 1998, 4:215-221.